{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:11:55Z","timestamp":1790802715195,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e28776","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T19:25:55Z","timestamp":1712345155000},"page":"e28776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"10","author":[{"given":"Rong","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3489-1959","authenticated-orcid":false,"given":"Fei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.heliyon.2024.e28776_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/jog.15267","article-title":"Vulvovaginal candidiasis: an overview of mycological, clinical, and immunological aspects","volume":"48","author":"Jafarzadeh","year":"2022","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"Suppl_2","key":"10.1016\/j.heliyon.2024.e28776_bib2","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/ciab1057","article-title":"Vulvovaginal candidiasis: a review of the evidence for the 2021 centers for disease control and prevention of sexually transmitted infections treatment guidelines","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28776_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/myc.13248","article-title":"Guideline: vulvovaginal candidosis (AWMF 015\/072, level S2k)","volume":"64","author":"Farr","year":"2021","journal-title":"Mycoses"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28776_bib4","first-page":"321","article-title":"Vaginitis: diagnosis and treatment","volume":"97","author":"Paladine","year":"2018","journal-title":"Am. Fam. Physician"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28776_bib5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/14656566.2018.1476490","article-title":"Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species","volume":"19","author":"Sobel","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28776_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11908-020-0712-7","article-title":"Fluconazole prophylaxis in prevention of symptomatic Candida vaginitis","volume":"22","author":"Story","year":"2020","journal-title":"Curr. Infect. Dis. Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28776_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/ajo.12592","article-title":"Recurrent vulvovaginal candidiasis: a review of guideline recommendations","volume":"57","author":"Matheson","year":"2017","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28776_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.annepidem.2017.08.010","article-title":"Recurrent vulvovaginal candidiasis","volume":"27","author":"Blostein","year":"2017","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.heliyon.2024.e28776_bib9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2217\/fmb-2021-0173","article-title":"Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis","volume":"16","author":"Sobel","year":"2021","journal-title":"Future Microbiol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28776_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jac\/dku355","article-title":"Antifungal drugs during pregnancy: an updated review","volume":"70","author":"Pilmis","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.heliyon.2024.e28776_bib11","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.2147\/IDR.S274872","article-title":"Candidemia: evolution of drug resistance and novel therapeutic approaches","volume":"14","author":"Tortorano","year":"2021","journal-title":"Infect. Drug Resist."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28776_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics9090539","article-title":"Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections","volume":"9","author":"Ghannoum","year":"2020","journal-title":"Antibiotics"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28776_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jof7030163","article-title":"Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor","volume":"7","author":"Jallow","year":"2021","journal-title":"J. Fungi"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e28776_bib14","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40265-021-01571-5","article-title":"Ibrexafungerp: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e28776_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01510-19","article-title":"Activity of a novel 1,3-beta-D-glucan synthase inhibitor, ibrexafungerp (formerly SCY-078), against Candida glabrata","volume":"63","author":"Ghannoum","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28776_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105922","article-title":"Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor)","volume":"55","author":"Zhu","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28776_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1358\/dot.2022.58.4.3381586","article-title":"Ibrexafungerp for the treatment of vulvovaginal candidiasis","volume":"58","author":"Sobel","year":"2022","journal-title":"Drugs Today"},{"key":"10.1016\/j.heliyon.2024.e28776_bib18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.12688\/f1000research.28327.1","article-title":"Novel antifungal agents in clinical trials","volume":"10","author":"Jacobs","year":"2021","journal-title":"F1000Res"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e28776_bib19","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41585-021-00522-9","article-title":"Ibrexafungerp to treat acute vulvovaginal candidiasis","volume":"18","author":"Masone","year":"2021","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28776_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/10600280221091301","article-title":"Ibrexafungerp in the treatment of vulvovaginal candidiasis","volume":"57","author":"Barnes","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e28776_bib21","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2024.e28776_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2024.e28776_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jclinepi.2021.08.022","article-title":"Cochrane's risk of bias tool for non-randomized studies (ROBINS-I) is frequently misapplied: a methodological systematic review","volume":"140","author":"Igelstrom","year":"2021","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28776_bib24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e28776_bib25","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e28776_bib26","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/cid\/ciab841","article-title":"Phase 2 randomized study of oral ibrexafungerp versus fluconazole in vulvovaginal candidiasis","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28776_bib28","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e28776_bib29","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28776_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational antifungal agents for invasive mycoses: a clinical perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin. Infect. Dis."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024048072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024048072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:51:14Z","timestamp":1773766274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024048072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2405844024048072"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28776","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28776"}}